Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recently, considerable interest has been directed to red-fluorescence photodiagnosis of brain and other tumours during surgery using the protoporphyrin IX natural precursor, 5-aminolaevulinic acid. In the present study we focused on the role of the rate-limiting enzyme
porphobilinogen deaminase
in
glioma
C6 cell activity, differentiation and sub-cellular distribution. Over-expression of the human housekeeping
porphobilinogen deaminase
in the
glioma
cells, using the housekeeping-
porphobilinogen deaminase
plasmid, induced a G1 cell cycle attenuation accompanied by increases in enzyme activity and c6 differentiation toward astrocytes. Visualisation of subcellular localisation of the
porphobilinogen deaminase
using the independent techniques of fluorescence immuno-staining with specific anti-human
porphobilinogen deaminase
antibodies and cellular expression of
porphobilinogen deaminase
fused to green fluorescent protein, revealed (unexpectedly) a major fraction of
porphobilinogen deaminase
in the nucleus and only a minor fraction in the cytoplasm. Both C and N terminals of
porphobilinogen deaminase
fused to green fluorescent protein revealed a major fraction of the newly synthesized fused
porphobilinogen deaminase
in the nucleus. Furthermore, newborn rat brain cells grown in a primary culture showed the same localisation pattern of
porphobilinogen deaminase
in the nuclei. Stimulation of C6
glioma
cell differentiation by butyrate induced a marked decrease in
porphobilinogen deaminase
both in the nucleus and in the cytoplasm as determined by Western blotting and fluorescence immuno-localisation. These findings suggest a possible dual role for housekeeping
porphobilinogen deaminase
in fast dividing
glioma
cells, one related to the porphyrin synthesis pathway and another coupled to nuclear function, which might be linked to tumorigenesis.
...
PMID:Nuclear distribution of porphobilinogen deaminase (PBGD) in glioma cells: a regulatory role in cancer transformation? 1195 37
In human
glioma
research, quantitative real-time reverse-transcription PCR is a frequently used tool. Considering the broad variation in the expression of candidate reference genes among tumor stages and normal brain, studies using quantitative RT-PCR require strict definition of adequate endogenous controls. This study aimed at testing a panel of nine reference genes [beta-2-microglobulin, cytochrome c-1 (CYC1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
hydroxymethylbilane synthase
, hypoxanthine guanine phosphoribosyl transferase 1, ribosomal protein L13a (RPL13A), succinate dehydrogenase, TATA-box binding protein and 14-3-3 protein zeta] to identify and validate the most suitable reference genes for expression studies in human
glioma
of different grades (World Health Organization grades II-IV). After analysis of the stability values calculated using geNorm, NormFinder, and BestKeeper algorithms, GAPDH, RPL13A, and CYC1 can be indicated as reference genes applicable for accurate normalization of gene expression in
glioma
compared with normal brain and anaplastic astrocytoma or glioblastoma alone within this experimental setting. Generally, there are no differences in expression levels and variability of candidate genes in
glioma
tissue compared to normal brain. But stability analyses revealed just a small number of genes suitable for normalization in each of the tumor subgroups and across these groups. Nevertheless, our data show the importance of validation of adequate reference genes prior to every study.
...
PMID:Selection of suitable reference genes for expression analysis in human glioma using RT-qPCR. 2586 7